Processing math: 100%
Review Topical Sections

Endoplasmic reticulum, oxidative stress and their complex crosstalk in neurodegeneration: proteostasis, signaling pathways and molecular chaperones

  • Cellular stress caused by protein misfolding, aggregation and redox imbalance is typical of neurodegenerative disorders such as Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Activation of quality control systems, including endoplasmic reticulum (ER)-mediated degradation, and reactive oxygen species (ROS) production are initially aimed at restoring homeostasis and preserving cell viability. However, persistent damage to macromolecules causes chronic cellular stress which triggers more extreme responses such as the unfolded protein response (UPR) and non-reversible oxidation of cellular components, eventually leading to inflammation and apoptosis. Cell fate depends on the intensity and duration of stress responses converging on the activation of transcription factors involved in the expression of antioxidant, autophagic and lysosome-related genes, such as erythroid-derived 2-related factor 2 (Nrf2) and transcription factor EB respectively. In addition, downstream signaling pathways controlling metabolism, cell survival and inflammatory processes, like mitogen activated protein kinase and nuclear factor-kB, have a key impact on the overall outcome.
    Molecular chaperones and ER stress modulators play a critical role in protein folding, in the attenuation of UPR and preservation of mitochondrial and lysosomal activity. Therefore, the use of chaperone molecules is an attractive field of investigation for the development of novel therapeutic strategies and disease-modifying drugs in the context of neurodegenerative diseases such as PD and ALS.

    Citation: Giulia Ambrosi, Pamela Milani. Endoplasmic reticulum, oxidative stress and their complex crosstalk in neurodegeneration: proteostasis, signaling pathways and molecular chaperones[J]. AIMS Molecular Science, 2017, 4(4): 424-444. doi: 10.3934/molsci.2017.4.424

    Related Papers:

    [1] H.Thomas Banks, Shuhua Hu . Nonlinear stochastic Markov processes and modeling uncertainty in populations. Mathematical Biosciences and Engineering, 2012, 9(1): 1-25. doi: 10.3934/mbe.2012.9.1
    [2] Ying He, Yuting Wei, Junlong Tao, Bo Bi . Stationary distribution and probability density function analysis of a stochastic Microcystins degradation model with distributed delay. Mathematical Biosciences and Engineering, 2024, 21(1): 602-626. doi: 10.3934/mbe.2024026
    [3] Aniello Buonocore, Luigia Caputo, Enrica Pirozzi, Amelia G. Nobile . A non-autonomous stochastic predator-prey model. Mathematical Biosciences and Engineering, 2014, 11(2): 167-188. doi: 10.3934/mbe.2014.11.167
    [4] Mainul Haque, John R. King, Simon Preston, Matthew Loose, David de Pomerai . Mathematical modelling of a microRNA-regulated gene network in Caenorhabditis elegans. Mathematical Biosciences and Engineering, 2020, 17(4): 2881-2904. doi: 10.3934/mbe.2020162
    [5] Dongchen Lu, Wei Han, Kai Lu . Identification of key microRNAs involved in tumorigenesis and prognostic microRNAs in breast cancer. Mathematical Biosciences and Engineering, 2020, 17(4): 2923-2935. doi: 10.3934/mbe.2020164
    [6] Shengjue Xiao, Yufei Zhou, Ailin Liu, Qi Wu, Yue Hu, Jie Liu, Hong Zhu, Ting Yin, Defeng Pan . Uncovering potential novel biomarkers and immune infiltration characteristics in persistent atrial fibrillation using integrated bioinformatics analysis. Mathematical Biosciences and Engineering, 2021, 18(4): 4696-4712. doi: 10.3934/mbe.2021238
    [7] Chris Cosner, Nancy Rodríguez . On the Allee effect and directed movement on the whole space. Mathematical Biosciences and Engineering, 2023, 20(5): 8010-8030. doi: 10.3934/mbe.2023347
    [8] Fan Zhang, Hongtao Liu . Identification of ferroptosis-associated genes exhibiting altered expression in pulmonary arterial hypertension. Mathematical Biosciences and Engineering, 2021, 18(6): 7619-7630. doi: 10.3934/mbe.2021377
    [9] Changxiang Huan, Jiaxin Gao . Insight into the potential pathogenesis of human osteoarthritis via single-cell RNA sequencing data on osteoblasts. Mathematical Biosciences and Engineering, 2022, 19(6): 6344-6361. doi: 10.3934/mbe.2022297
    [10] Guilherme Giovanini, Alan U. Sabino, Luciana R. C. Barros, Alexandre F. Ramos . A comparative analysis of noise properties of stochastic binary models for a self-repressing and for an externally regulating gene. Mathematical Biosciences and Engineering, 2020, 17(5): 5477-5503. doi: 10.3934/mbe.2020295
  • Cellular stress caused by protein misfolding, aggregation and redox imbalance is typical of neurodegenerative disorders such as Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Activation of quality control systems, including endoplasmic reticulum (ER)-mediated degradation, and reactive oxygen species (ROS) production are initially aimed at restoring homeostasis and preserving cell viability. However, persistent damage to macromolecules causes chronic cellular stress which triggers more extreme responses such as the unfolded protein response (UPR) and non-reversible oxidation of cellular components, eventually leading to inflammation and apoptosis. Cell fate depends on the intensity and duration of stress responses converging on the activation of transcription factors involved in the expression of antioxidant, autophagic and lysosome-related genes, such as erythroid-derived 2-related factor 2 (Nrf2) and transcription factor EB respectively. In addition, downstream signaling pathways controlling metabolism, cell survival and inflammatory processes, like mitogen activated protein kinase and nuclear factor-kB, have a key impact on the overall outcome.
    Molecular chaperones and ER stress modulators play a critical role in protein folding, in the attenuation of UPR and preservation of mitochondrial and lysosomal activity. Therefore, the use of chaperone molecules is an attractive field of investigation for the development of novel therapeutic strategies and disease-modifying drugs in the context of neurodegenerative diseases such as PD and ALS.


    This paper is concerned with a mathematical model for a gene regulatory network involved in the regulation of DNA transcription. DNA transcription is part of the mechanism by which a sequence of the nuclear DNA is translated into the corresponding protein. The transcription is initiated by the binding of a transcription factor, which is usually another protein, onto the gene's DNA-binding domain. Once bound, the transcription factor promotes the transcription of the nuclear DNA into a messenger RNA (further denoted by mRNA), which, once released, is translated into the corresponding protein by the ribosomes. This process is subject to a high level of noise due to the large variability of the conditions that prevail in the cell and the nucleus at the moment of the transcription. Yet, a rather stable amount of the final protein is needed for the good operation of the cell. The processes that regulate noise levels and maintain cell homeostasis have been scrutinized for a long time. Recently, micro RNAs (further referred to as μRNAs) have occupied the front of the scene. These are very short RNAs which do not code for proteins. Many different sorts of μRNAs are involved in various epigenetic processes. But one of their roles seems precisely the reduction of noise level in DNA transcription. In this scenario, the μRNAs are synthesized together with the mRNAs. Then, some of the synthesized μRNAs bind to the mRNAs and de-activate them. These μRNA-bound mRNA become unavailable for protein synthesis. It has been proposed that this paradoxical mechanism which seems to reduce the efficiency of DNA transcription may indeed have a role in noise regulation (see [1,2,3] and the review [4]). The goal of the present contribution is to propose a mathematical model of the μRNA-mRNA interaction and to use it to investigate the role of μRNAs as potential noise regulators.

    Specifically, in this paper, we propose a stochastic chemical kinetic model for the mRNA and μRNA content in a cell. The production of mRNAs by the transcription factor and their inactivation through μRNA binding are taken into account. More precisely, our model is a simplified version of the circuit used in [5,Figure 2A,A']. We consider a ligand involved in the production of both an mRNA and a μRNA, the μRNA having the possibility to bind to the mRNA and deactivate it. By contrast to [5], we disregard the way the ligand is produced and consider that the ligand is such that there is a constant production rate of both mRNA and μRNA. A second difference to [5] is that we disregard the transcription step of the mRNA into proteins. While [5] proposes to model the μRNA as acting on translation, we assume that the μRNA directly influences the number of mRNA available for transcription. Therefore, we directly relate the gene expression level to the number of μRNA-free mRNA also referred to as the number of unbound mRNA. In order to model the stochastic variability in the production of the RNAs, a multiplicative noise is added to the production rate at all time. From the resulting system of stochastic differential equations, we introduce the joint probability density for mRNA and μRNA which solves a deterministic Fokker-Planck equation. The mathematical object of interest is the stationary density solving the Fokker-Planck equation and more precisely the marginal density of the mRNA. The coefficient of variation (also called cell-to-cell variation) of this mRNA density, which is its standard deviation divided by its the expectation, is often considered as the relevant criterion for measuring the robustness of gene expression (see for instance [5]).

    Figure 1.  Exploration of the parameter space. Relative cell to cell variation CV(ρδ,γ,pfast)/CV(ρδ0) for various parameters p, γ and δ. On the horizontal axis, left means more production of mRNA and right means more production of μRNA; On the vertical axis, top means more destruction of mRNA by binding and bottom means more destruction/consumption of mRNA by other mechanisms.
    Figure 2.  Marginal distributions of mRNAs ρδ,γ,pfast for fast μRNAs compared to the free mRNA distribution ρδ0 (black solid curve) for different parameters p and γ. Left: δ=2, p=1.5 and γ varies. Right: δ=2, γ=1 and p varies.

    Our main goal in this contribution is to provide theoretical and numerical evidence that the robustness of the gene expression is increased in the presence of μRNA. At the theoretical level we derive a number of analytical formulas either for particular subsets of parameters of the model or under some time-scale separation hypotheses. From these formulas we can easily compute the cell to cell variation numerically and verify the increased robustness of gene expression when binding with μRNA happens in the model. For general sets of parameters, the solution cannot be computed analytically. However we can prove well-posedness of the model and solve the PDE with a specifically designed numerical scheme. From the approximate solution, we compute the coefficient of variation and verify the hypothesis of increased gene expression.

    Another classical approach to the study of noise in gene regulatory networks is through the chemical master equation [6] which is solved numerically by means of Gillespie’s algorithm [7], see e.g., [5,8]. Here, we use a stochastic chemical kinetic model through its associated Kolmogorov-Fokker-Planck equation. Chemical kinetics is a good approximation of the chemical master equation when the number of copies of each molecule is large. This is not the case in a cell where sometimes as few as a 100 copies of some molecules are available. Specifically, including a stochastic term in the chemical kinetic approach is a way to retain some of the randomness of the process while keeping the model complexity tractable. This ultimately leads to a Fokker-Planck model for the joint distribution of mRNAs and μRNAs. In [9], a similar chemical kinetic model is introduced with a different modelling of stochasticity. The effect of the noise is taken into account by adding some uncertainty in the (steady) source term and the initial data. The authors are interested in looking at how this uncertainty propagates to the mRNA content and in comparing this uncertainty between situations including μRNA production or not. The uncertainty is modeled by random variables with given probability density functions. Compared to [9], the Fokker-Planck approach has the advantage that the random perturbations do not only affect the initial condition and the source term, but are present at all times and vary through time. We believe that this is coherent with how stochasticity in a cell arises through time-varying ecological or biological factors.

    While Fokker-Planck equations are widely used models in mathematical biology [10], their use for the study of gene regulatory network is, up to our knowledge, scarce (see e.g., [11]). Compared to other approaches, the Fokker-Planck model enables us to derive analytical formulas for solutions in certain cases. This is particularly handy for understanding the role of each parameter in the model, calibrating them from real-world data and perform fast numerical computations. Nevertheless, in the general case, the theoretical study and the numerical simulation of the model remains challenging because of the unboundedness of the drift and diffusion coefficients. We believe that we give below all the tools for handling these difficulties, and that our simple model provides a convincing mathematical interpretation of the increase of gene expression in the presence of μRNAs.

    The paper is organized as follows. In Section 2, we introduce the system of SDEs and the corresponding Fokker-Planck models. In Section 3, we discuss the well-posedness of the Fokker-Planck equations and derive analytical formulas for solutions under some simplifying hypotheses. In Section 4, we use the analytical formulas for solutions to give mathematical and numerical proofs of the decrease of cell-to-cell variation in the presence of μRNA. In Section 5, we propose a numerical scheme for solving the main Fokker-Planck model and gather further evidence confirming the hypothesis of increased gene expression from the simulations. Finally, in Section 6 we discuss the particular choice of multiplicative noise (i.e., the diffusion coefficient in the Fokker-Planck equation) in our model. In the appendix, we derive weighted Poincaré inequalities for gamma and inverse-gamma distributions which are useful in the analysis of Section 3. The code used for numerical simulations in this paper is publicly available on GitLab [12].

    In this section, we introduce three steady Fokker-Planck models whose solutions describe the distribution of unbound mRNA and μRNA within a cell. The solutions to these equations can be interpreted as the probability density functions associated with the steady states of stochastic chemical kinetic systems describing the production and destruction of mRNA and μRNA. In Section 2.1 we introduce the main model for which the consumption of RNAs is either due to external factors in the cell (translation, {etc.}) or to binding between the two types of mRNA and μRNA. Then, for comparison, in Section 2.2 we introduce the same model without binding between RNAs. Finally in Section 2.3, we derive an approximate version of the first model, by considering that reactions involving μRNAs are infinitely faster than those involving mRNAs, which amplifies the binding phenomenon and mathematically allows for the derivation of analytical formulas for solutions. The latter will be made explicit in Section 3.

    We denote by rt the number of unbound mRNA and μt the number of unbound μRNA of a given cell at time t. The kinetics of unbound mRNA and μRNA is then given by the following stochastic differential equations

    {drt=(crcrtμtkrrt)dt+ 2σrrtdB1t,dμt=(cμcrtμtkμμt)dt+2σμμtdB2t, (2.1)

    with cr, cμ, kr, kμ, σr, σμ being some given positive constants and c being a given non-negative constant. Let us detail the meaning of each term in the modeling. The first term of each equation models the constant production of mRNA (resp. μRNA) by the ligand at a rate cr (resp. cμ). The second term models the binding of the μRNA to the mRNA. Unbound mRNA and μRNA are consumed by this process at the same rate. The rate increases with both the number of mRNA and μRNA. In the third term, the parameters kr and kμ are the rates of consumption of the unbound mRNA or μRNA by various decay mechanisms. The last term in both equations represents stochastic fluctuations in the production and destruction mechanisms of each species. It relies on a white noise dBt/dt where Bt=(B1t,B2t) is a two-dimensional standard Brownian motion. The intensity of the stochastic noise is quantified by the parameters 2σrrt and 2σμμt. Such a choice of multiplicative noise ensures that rt and μt remain non-negative along the dynamics. The Brownian motions B1t and B2t are uncorrelated. The study of correlated noises or the introduction of extrinsic noise sources would be interesting, but will be discarded here.

    In this paper we are interested in the invariant measure of Eq (2.1) rather than the time dynamics described by the above SDEs. From the modelling point of view, we are considering a large number of identical cells and we assume that mRNA and μRNA numbers evolve according to Eq (2.1). Then we measure the distribution of both RNAs among the population, when it has reached a steady state ff(r,μ). According to Itô's formula, the steady state should satisfy the following steady Fokker-Planck equation

    {Lf(r,μ) = 0,(r,μ)Ω=(0,)2,Ωf(r,μ)drdμ = 1,f(r,μ)  0. (2.2)

    where the Fokker-Planck operator is given by

    Lf(r,μ) := r[r(σrr2f)(crcrμkrr)f]+μ[μ(σμμ2f)(cμcrμkμμ)f]. (2.3)

    Since we do not model the protein production stage, we assume that the observed distribution of gene expression level is proportional to the marginal distribution of mRNA, i.e..

    ρ(r)=0f(r,μ)dμ.

    By integration of Eq (2.2) in the μ variable, ρ satisfies the equation

    r[r(σr r2 ρ)( crc r jμ(r)kr r)ρ]=0. (2.4)

    The quantity jμ(r) is the conditional expectation of the number of μRNA within the population in the presence of r molecules of mRNA and it is given by

    jμ(r)=1ρ(r)μ f(r,μ)dμ. (2.5)

    Before ending this paragraph, we note an alternate way to derive the Fokker-Planck Eq (2.2) from the chemical master equation through the chemical Langevin equation. We refer the interested reader to [13].

    In the case where there is no μRNA binding, namely when c=0, the variables r and μ are independent. Thus, the densitites of the invariant measures satisfying Eq (2.2) are of the form

    f0(r,μ)=ρ0(r)λ(μ),

    where λ(μ) is the density of the marginal distrubution of μRNA. From the modelling point of view, it corresponds to the case where there is no feed-forward loop from μRNA. Therefore, only the dynamics on mRNA, and thus ρ0, is of interest in our study. It satisfies the following steady Fokker-Planck equation obtained directly from Eq (2.4),

    {r[σrr(r2ρ0)(crkrr)ρ0] = 0,0ρ0(r)dr = 1,ρ0(r)0. (2.6)

    It can be solved explicitly as we will discuss in Section 3.2.

    The Fokker-Planck Eq (2.2) cannot be solved explicitly. However, one can make some additional assumptions in order to get an explicit invariant measure providing some insight into the influence of the binding mechanism with μRNA. This is the purpose of the model considered hereafter.

    Let us assume the μRNA-mRNA binding rate, the μRNA decay and the noise on μRNA are large. Since the sink term of the μRNA equation is large, it is also natural to assume that the μRNA content is small. Mathematically, we assume the following scaling

    c=˜cε,kμ=˜kμε,σμ=˜σμε,μt=ε~μt,

    for some small constant ε>0. Then (rt,˜μt) satisfies

    {drt=(cr˜crt˜μt˜krrt)dt+ 2σrrtdB1t,εd˜μt=(cμ˜crt˜μt˜kμ˜μt)dt+2ε˜σμ˜μtdB2t,

    whose corresponding steady Fokker-Planck equation for the invariant measure then writes, dropping the tilde,

    r[r(σrr2fε)(crcrμkrr)fε]+1εμ[μ(σμμ2fε)(cμcrμkμμ)fε] = 0.

    In the limit case where ε0, one may expect that at least formally, the density fε converges to a limit density ffast satisfying

    μ[μ(σμμ2ffast)(cμcrμkμμ)ffast] = 0.

    As r is only a parameter in the previous equation and since the first marginal of fε still satisfies Eq (2.4) for all ε, one should have (formally)

    {ffast(r,μ) = ρfast(r)M(r,μ)  0,μ[μ(σμμ2M)(cμcrμkμμ)M] = 0,r[r(σr r2 ρfast)( crc r jfast(r)kr r)ρfast]=0,0ρfast(r)dr = 1, 0M(r,μ)dμ = 1,jfast(r) = 0μ M(r,μ)dμ. (2.7)

    In this section, we show that the three previous models are well-posed. For the Fokker-Planck Eqs (2.6) and (2.7), we explicitly compute the solutions. They involve inverse gamma distributions.

    The expressions of the gamma and inverse gamma probability densities are respectively

    γα,β(x) = Cα,βxα1exp(βx), (3.1)

    and

    gα,β(y) = Cα,βy1+αexp(βy), (3.2)

    for x,y(0,). The normalization constant is given by Cα,β=βα/Γ(α) where Γ is the Gamma function. Observe that by the change of variable y=1/x one has

    gα,β(y)dy = γα,β(x)dx

    which justifies the terminology. Let us also recall that the first and second moments of the inverse gamma distribution are

    0ygα,β(y)dy = βα1, if α>1, β>0, (3.3)
    0y2gα,β(y)dy = β2(α1)(α2), if α>2, β>0, (3.4)

    Interestingly enough, we can show (see Appendix A.1 for details and additional results) that inverse gamma distributions with finite first moment (α>1) satisfy a (weighted) Poincaré inequality. The proof of the following proposition is done in Appendix A.1 among more general considerations.

    Proposition 3.1. Let α>1 and β>0. Then, for any function v such that the integrals make sense, one has

    0|v(y)vgα,β|2gα,β(y)dy  1α10|v(y)|2gα,β(y)y2dy, (3.5)

    where for any probability density ν and any function u on (0,), the notation uν denotes uν.

    In the case of free mRNAs, a solution to Eq (2.6) can be computed explicitely and takes the form of an inverse gamma distribution.

    Lemma 3.2. The following inverse gamma distribution

    ρ0(r) = g1+krσr,crσr(r) = C1+krσr,crσr1r2+krσrexp(crσrr) (3.6)

    is the only classical solution to Eq (2.6).

    Proof. First observe that

    r[σrr(r2ρ0)(crkrr)ρ0] = r[σrr2g1+krσr,crσrr(ρ0g11+krσr,crσr)].

    Therefore a solution of Eq (3.1) must be of the form

    ρ0(r) = C1g1+krσr,crσrr1σ1rr2g11+krσr,crσr(r)dr+C2g1+krσr,crσr,

    for some constants C1,C2. The first term decays like 1/r at infinity, thus the only probability density ρ0 of this form is obtained for C1=0 and C2=1.

    The Poincaré inequality (3.5) tells us that the solution of Lemma 3.2 is also the only (variational) solution in the appropriate weighted Sobolev space. Indeed, we may introduce the natural Hilbert space associated with Eq (2.6),

    Xα,β = {v:(0,)R, vXα,β<}

    with a squared norm given by

    v2Xα,β = 0([(v/gα,β)(y)]2+[(v/gα,β)(y)]2y2)gα,β(y)dy.

    Then the following uniqueness result holds.

    Lemma 3.3. The classical solution ρ0=g1+krσr,crσr is the only solution of Eq (2.6) in X1+krσr,crσr.

    Proof. If ρ0 and ~ρ0 are two solutions of Eq (2.6), a straightforward consequence of inequality (3.5) is that ρ0~ρ0X1+krσr,crσr=0. This is obtained by integrating the difference between the equation on ρ0 and ~ρ0 against (ρ0~ρ0)g11+krσr,crσr.

    Another consequence of the Poincaré inequality is that if we consider the time evolution associated with Eq (2.6) then solutions converge exponentially fast towards the steady state ρ0. This justifies our focus on the stationary equations. The transient regime is very short and equilibrium is reached quickly. We can quantify the rate of convergence in terms of the parameters.

    Proposition 3.4. Let ξ solve the Fokker-Planck equation

    tξ(t,r) = r[σrr(r2ξ(t,r))(crkrr)ξ(t,r)],

    starting from the probability density ξ(0,r,μ)=ξin(r,μ). Then for all t0,

    0(ξ(t,r)ρ0(r))2g11+krσr,crσr(r)dr ekrσrt0(ξin(r)ρ0(r))2g11+krσr,crσr(r)dr.

    Proof. Observe that ξρ0 solves the unsteady Fokker-Planck equation, so that by multiplying the equation by (ξρ0)g11+krσr,crσr and integrating in r one gets

    ddt0(ξ(t,r)ρ0(r))2g11+krσr,crσr(r)dr+0|r(ξ(t,)ρ0g1+krσr,crσr)(r)|2g1+krσr,crσr(r)r2dr = 0.

    Then by using the Poincaré inequality Eq (3.5) and a Gronwall type argument, one gets the result.

    Now we focus on the solution of Eq (2.7). The same arguments as those establishing Lemma 3.3 show that the only function M satisfying Eq (2.7) is the following inverse gamma distribution

    M(r,μ) = g1+kμσμ+cσμr,cμσμ(μ). (3.7)

    Then an application of Eq (3.3) yields

    jfast(r)=cμkμ+cr. (3.8)

    It remains to find ρfast which is a probability density solving the Fokker-Planck equation

    r[r(σr r2 ρfast)( crcμcrkμ+crkr r)ρfast]=0.

    Arguing as in the proof of Lemma 3.2, one observe that integrability properties force ρfast to actually solve

    r(σr r2 ρfast)( crcμcrkμ+crkr r)ρfast=0.

    which yields

    ρfast(r) = C(1+kμcr)ccμσrkμ1r2+krσrexp(crσrr) (3.9)

    where CC(cr,cμ,kr,kμ,σr,σμ,c) is a normalizing constant making ρfast a probability density function.

    Now we are interested in the well-posedness of Eq (2.2), for which we cannot derive explicit formulas anymore. Despite the convenient functional framework introduced in Section 3.2, classical arguments from elliptic partial differential equation theory do not seem to be adaptable to the case c>0. The main obstruction comes from an incompatibility between the natural decay of functions in the space Xα,β and the rapid growth of the term crμ when |(r,μ)|.

    However, thanks to the results of [14] focused specifically on Fokker-Planck equations, we are able to prove well-posedness of the steady Fokker-Planck Eq (2.2). The method is based on finding a Lyapunov function for the adjoint of the Fokker-Planck operator and relies on an integral identity proved by the same authors in [15]. The interested reader may also find additional material and a comprehensive exposition concerning the analysis of general Fokker-Planck equations for measures in [16].

    First of all let us specify the notion of solution. A weak solution to Eq (2.2) is an integrable function f such that

    {Ωf(r,μ)Lφ(r,μ) = 0,for all φCc(Ω),Ωf(r,μ) = 1,f(r,μ)  0, (3.10)

    where the adjoint operator is given by

    Lφ(r,μ) := σrr22rrφ+(crcrμkrr)rφ+σμμ22μμφ+(cμcrμkμμ)μφ. (3.11)

    A reformulation and combination of [14,Theorem A and Proposition 2.1] provides the following result.

    Proposition 3.5 ([14]). Assume that there is a smooth function U:Ω[0,+), called Lyapunov function with respect to L, such that

    lim(r,μ)¯ΩU(r,μ) = +, (3.12)

    and

    lim(r,μ)¯ΩLU(r,μ) = , (3.13)

    where ¯Ω=Ω({+}×R+)(R+×{+}). Then there is a unique f satisfying Eq (3.10). Moreover fW1,loc(Ω).

    Remark 3.6. The method of Lyapunov functions is a standard tool for proving well-posedness of many problems in the theory of ordinary differential equations, dynamical systems... For diffusion processes and Fokker-Planck equations its use dates back to Has'minskii [17]. We refer to [16,Chapter 2], [14] and references therein for further comments on the topic. Let us stress however that Lyapunov functions are not related (at least directly) to the Lyapunov (or entropy) method for evolution PDEs in which one shows the monotony of a functional to quantify long-time behavior.

    Remark 3.7. Thanks of the degeneracy of the diffusivities at r=0 and μ=0 and the Lyapunov function condition, one doesn't need supplementary boundary conditions in Eq (3.10) for the problem to have a unique solution. This is different from standard elliptic theory where boundary conditions are necessary to define a unique solution when the domain and the coefficients are bounded with uniformly elliptic diffusivities. Further comments may be found in [14].

    Lemma 3.8. Choose any two constants br>ckμ and bμ>ckr. Then, the function U:ΩR defined by

    U(r,μ) = brrln(brr)+bμμln(bμμ)

    is a Lyapunov function with respect to L (i.e., it is positive on Ω and it satisfies Eqs (3.12) and (3.13)).

    Proof. First observe that condition (3.12) is clearly satisfied. Also, U is minimal at (b1r,b1μ) where it takes the value 2 and thus it is positive on Ω. Finally a direct computation yields

    LU(r,μ) = (σr+σμ+brcr+bμcμ+kr+kμ)crrcμμ(brkrc)r(bμkμc)μcrμ(br+bμ),

    and Eq (3.13) follows. Now we state our well-posedness result for the Fokker-Planck Eq (3.10).

    Proposition 3.9. There is a unique weak solution f to the steady Fokker-Planck Eq (2.2). Moreover, f is indefinitely differentiable in Ω.

    Proof. The existence and uniqueness of a solution fW1,loc(Ω) is a combination of Proposition 3.5 and Lemma 3.8. From there in any smooth compact subdomain K⊂⊂Ω, we get from standard elliptic theory [18] that fC(K), since the coefficents are smooth and the operator is uniformly elliptic.

    In this section we focus on the comparison between the explicit distributions given by Eqs (3.6) and (3.9). We are providing theoretical and numerical evidence that the coefficient of variation (which is a normalized standard deviation) of distribution (3.9) is less than that of distribution (3.6). This quantity called cell to cell variation in the biological literature [5] characterizes the robustness of the gene expression level (the lower the better). We start by performing a rescaling in order to extract the dimensionless parameters which characterize the distributions.

    In order to identify the parameters of importance in the models, we rescale the variables r and μ around characteristic values ˉr and ˉμ chosen to be

    ˉr=crkrandˉμ = cμkμ. (4.1)

    These choices are natural in the sense that they correspond to the steady states of the mRNA and μRNA dynamics without binding nor stochastic effects, that is respectively drt=(crkr rt)dt and dμt=(cμkμ μt)dt. When the noise term is added, it still corresponds to the expectation of the invariant distribution, that is the first moment of ρ0 in the case of mRNA. We introduce fad such that for all (r,μ)Ω one has

    1ˉrˉμfad(rˉr,μˉμ) = f(r,μ).

    After some computations one obtains that the Fokker-Planck Eqs (2.2) and (2.3) can be rewritten in terms of fad as

    r[δ(1γprμr)fadr(r2fad)]+ μ[δκ(1γrμμ)fadνμ(μ2fad)] = 0, (4.2)

    The marginal distributions ρ0 and ρfast are rescaled into dimensionless densities

    ρδ0(r) = g1+δ,δ(r) = Cad01r2+δexp(δr) (4.3)
    ρδ,γ,pfast(r) = Cadfast(1+1γr)γpδ1r2+δexp(δr) (4.4)

    where Cad0 and Cadfast are normalizing constants depending on the parameters of the model and δ, p and γ are dimensionless parameters. The first parameter

    δ = krσr, (4.5)

    only depends on constants that are independent of the dynamics of μRNAs. The two other dimensionless parameters appearing in the marginal distribution of mRNA in the presence of fast μRNA are

    p = cμcr, (4.6)

    and

    γ = cˉrkμ = ccrkμkr. (4.7)

    Let us give some insight into the biological meaning of these parameters. The parameter γ measures the relative importance of the two mechanisms of destruction of μRNAs, namely the binding with mRNAs versus the natural destruction/consumption. A large γ means that the binding effect is strong and conversely. The parameter p compares the production rate of μRNAs with that of mRNAs. Large values of p mean that there are much more μRNAs than mRNAs produced per unit of time.

    Finally, in the Fokker-Planck model (4.2), there are also two other parameters which are

    κ = kμkr, (4.8)

    and

    ν = σμσr. (4.9)

    The parameter κ compares consumption of μRNA versus that of mRNA by mechanisms which are not the binding between the two RNAs. The parameter ν compares the amplitude of the noise in the dynamics of μRNA versus that of the mRNA.

    Remark 4.1. Observe that the approximation of fast μRNA leading to the model discussed in Section 2.3 in its dimensionless form amounts to taking ν=κ=1/ε and letting ε tend to 0.

    For any suitably integrable non-negative function ν, let us denote by

    mk(ν) = ykν(y)dy

    its k-th moment. The coefficient of variation or cell to cell variation (CV) is defined by

    CV(ν) = Var(ν/m0(ν))1/2Exp(ν/m0(ν)) = (m2(ν)m0(ν)m1(ν)21)1/2 (4.10)

    where Exp() and Var() denote the expectation and variance. Let us state a first lemma concerning some cases where the coefficient of variation can be computed exactly.

    Lemma 4.2. Consider the dimensionless distributions defined in Eqs (4.3) and (4.4). Then one has that

    Exp(ρδ0) = 1,Var(ρδ0) = 1δ1,CV(ρδ0) = 1δ1, (4.11)

    where the variance and coefficient of variation are well-defined only for δ>1. Then for any δ>1, the following limits holds

    limγ0CV(ρδ,γ,pfast)=CV(ρδ0),p>0,limp0CV(ρδ,γ,pfast)=CV(ρδ0),γ>0,limγCV(ρδ,γ,pfast)=CV(ρδ0),p[0,1).

    Proof. The formulas for the moments follow from Eqs (3.3) and (3.4). Then observe that for all r, one has

    limγ0ρδ,γ,pfast(r) = limp0ρδ,γ,pfast(r) =ρδ0(r)

    and

    limγ+ρδ,γ,pfast(r) = g1+δ,(1p)δ(r)

    and one can then take limits in integrals by dominated convergence.

    Let us give a biological interpretation of the previous lemma. When γ=0 or p=0, which respectively corresponds to the cases where there is no binding between mRNA and μRNA or there is no production of μRNA, the coefficient of variation is unchanged from the case of free mRNAs. The last limit states that if the μRNA production is weaker than the mRNA production, then in the regime where all μRNA is consumed by binding with mRNA, the coefficient of variation is also unchanged.

    Outside of these asymptotic regimes, the theoretical result one would like to have is the following.

    Conjecture 4.3. For any δ>1, γ,p>0 and one has CV(ρδ,γ,pfast)  CV(ρδ0).

    At the moment, we are able to obtain the following uniform in γ and p bound

    CV(ρδ,γ,pfast)  Cδ := ((δδ1)2(11(δ1)2)δ21)12, (4.12)

    which holds for all δ>2, γ>0 and p0. The result is proved in Proposition in the Appendix. Observe that CδCV(ρδ0) but asymptotically

    CδδCV(ρδ0) = 1δ1,

    so that Cδ is fairly close to CV(ρδ0) for large δ.

    In the next section we provide numerical evidence that it should be possible to improve the right-hand side of the bound (4.12) and prove Conjecture 4.3. Let us also mention that using integration by parts formulas it is possible to establish a recurrence relation between moments. From there one can infer the inequality of Conjecture 4.3 for subsets of parameters (γ,p). As the limitation to these subsets is purely technical and do not have any particular biological interpretation we do not report these results here.

    Now, we explore the space of parameters (δ,γ,p) in order to compare the cell to cell variation in the case of fast μRNA and in the case of free mRNA.

    In order to evaluate numerically the cell to cell variation we need to compute mk(ρδ,γ,pfast), for k=0,1,2. Observe that after a change of variable these quantities can be rewritten (up to an explicit multiplicative constant depending on parameters)

    Ik=0fk(s)sδ2esds,

    with fk(s)=s2k(1+s/(γδ))pγδ. For the numerical computation of these integrals, we use a Gauss-Laguerre quadrature

    Ik  Ni=1ωNifk(xNi).

    which is natural and efficient as we are dealing with functions integrated against a gamma distribution. We refer to [19] and references therein for the definition of the coefficients ωNi and quadrature points xNi. The truncation order N is chosen such that the numerical error between the approximation at order N and N+1 is inferior to the given precision 108 when p1. For p1, the function fk may take large values and it is harder to get the same numerical precision. In the numerical results below the mean error for the chosen sets of parameters with large values of p is around 104 and the maximal error is 102. This is good enough to comment on qualitative behavior. The code used for these numerical simulations is publicly available on GitLab [12].

    We plot the relative cell to cell variation CV(ρδ,γ,pfast)/CV(ρδ0) with respect to γ and p for two different values of δ. The results are displayed on Figure 1. Then, on Figure 2, we draw the explicit distributions ρδ,γ,pfast for various sets of parameters and compare it with ρδ0.

    The numerical simulations of Figure 1 suggest that the bound (4.12) is non-optimal and Conjecture 4.3 should be satisfied. Observe also that the asymptotics of Lemma 4.2 are illustrated.

    From a modeling point of view, these simulations confirm that for any choice of parameter, the presence of (fast) μRNA makes the cell to cell variation decrease compared to the case without μRNA. Moreover, the qualitative behavior with respect to the parameters makes sense. Indeed we observe that whenever enough μRNA is produced (p1), the increase of the binding phenomenon (γ) makes the cell to cell variation decay drastically.

    In this section, we compute the gene expression level of the main model described by Eq (2.2). In this case, as there is no explicit formula for the solution, we will compute an approximation of it using a discretization of the Fokker-Planck equation. In order to compute the solution in practice, we restrict the domain to the bounded domain Ωb=[rmin,rmax]×[μmin,μmax]. Because of the truncation, we add zero-flux boundary conditions in order to keep a conservative equation. It leads to the problem

    {r[(crcrμkrr)fr(σrr2f)]+ μ[(cμcrμkμμ)fμ(σμμ2f)] = 0,in Ωbr(σrr2f)(crcrμkrr)f=0, if r=rmin or rmax,μ(σμμ2f)(cμcrμkμμ)f=0, if μ=μmin or μmax,Ωbfdrdμ = 1.  (5.1)

    In order for the numerical scheme to be more robust with respect to the size of the parameters, we discretize the equation in dimensionless version according to Eq (4.2). It will also allow for comparisons with numerical experiments of the previous sections.

    As the coefficients in the advection and diffusion parts of Eq (4.2) grow rapidly in r, μ and degenerate when r=0 and μ=0, the design of an efficient numerical solver for Eq (4.2) is not straightforward. Moreover a desirable feature of the scheme would be a preservation of the analytically known solution corresponding to γ=0. Because of these considerations we will discretize a reformulated version of the equation in which the underlying inverse gamma distributions explicitly appear. It will allow for a better numerical approximation when r and μ are either close to 0 or large. The reformulation is the following

    r[r2h(1)(r,μ)r(fadh(1)(r,μ))]μ[νμ2h(2)(r,μ)μ(fadh(2)(r,μ))] = 0, (5.2)

    with the associated no-flux boundary conditions and where the functions h(1) and h(2) are given by

    h(1)(r,μ) = r(1+pμγ)δ2exp(δr), (5.3)

    and

    h(2)(r,μ) = μ(1+rγ)δκν2exp(δκνr). (5.4)

    We use a discretization based on the reformulation (5.2). It is inspired by [20] and is fairly close to the so-called Chang-Cooper scheme [21].

    We use a finite-volume scheme. The rectangle Ωb is discretized with a structured regular mesh of size Δr and Δμ in each respective direction. The centers of the control volumes are the points (ri,μj) with ri=Δr/2+iΔr and μj=Δμ/2+jΔμ for i{0,,Nr1} and j{0,,Nμ1}. We also introduce the intermediate points ri+1/2 with i{1,,Nr1} and μj+1/2 with j{1,,Nμ1} defined with the same formula as before. The approximation of the solution on the cell (i,j) is denoted by

    fij1ΔrΔμri+1/2ri1/2μj+1/2μj1/2fad(r,μ)drdμ.

    The scheme reads, for all i{0,,Nr1} and j{0,,Nμ1},

    {Fi+1/2,jFi1/2,j+Gi,j+1/2Gi,j1/2=0,FNr1/2,j = F1/2,j = Gi,Nμ1/2 = Gi,1/2 = 0i,jfijΔrΔμ = 1 (5.5)

    where the fluxes are given by a centered discretization of the reformulation (5.2), namely

    Fi+1/2,j=ΔμΔrr2i+1/2(h(1)(ri+1/2,μj)h(1)(ri+1,μj)fi+1,jh(1)(ri+1/2,μj)h(1)(ri,μj)fij), (5.6)

    and

    Gi,j+1/2=νΔrΔμμ2j+1/2(h(2)(ri,μj+1/2)h(2)(ri,μj+1)fi,j+1h(2)(ri,μj+1/2)h(2)(ri,μj)fij). (5.7)

    One can show that the scheme (5.5) possesses a unique solution which is non-negative by following, for instance, the arguments of [22,Proposition 3.1]. Moreover, by construction, the scheme is exact in the case γ=0.

    Remark 5.1 (Choice of rmin, rmax, μmin, μmax). Clearly f decays faster at infinity than ρ0 since the convection term coming from the binding phenomenon brings mass closer to the origin. Therefore an appropriate choice for rmax and μmax, coming from the decay of the involved inverse gamma distributions, should be (say) rδmax108 and μδκ/νmax108 so that the error coming from the tails of the distributions in the computation of moments is negligible. Similarly, near the origin the distributions decay very quickly to 0 (as exp(1/)). Therefore μmin, rmin can be taken not too small without influencing the precision in the computation of moments of the solution. In practice, we chose μmin=rmin=0.06. Observe that even if nothing prevents the choice μmin=rmin=0 on paper, one experiences in practice a bad conditioning of the matrix which has to be inverted for solving the scheme.

    Remark 5.2 (Implementation). Observe that the matrix which has to be inverted in order to solve the scheme is not a square matrix because of the mass constraint (which is necessary to ensure uniqueness of the solution). In practice, in order to solve the corresponding linear system MF=B where F=(fij)ij and B=(0,,0,1)RNrNμ+1 and MR(NrNμ+1)×NrNμ we use the pseudo-inverse yielding F=(MtM)1MtB. Finally the use of a sparse matrix routine greatly improves the computation time. Our implementation was made using Matlab. The code is publicly available on GitLab [12].

    In our test cases we use the following parameters: rmin=0.06, rmax=5, μmin=0.05, μmax=5, δ=8, Nr=70, Nμ=200, κ=1, ν=1.

    On Figure 3 we compare the distribution functions f(r,μ) obtained for various sets of parameters (p,γ). We also draw the corresponding marginal ρ(r) as well as ρ0 and ρfast. We observe that for small values of p, ρfast is a good approximation of ρ. For larger values it tends to amplify the phenomenon of variance reduction.

    Figure 3.  Numerical results. Numerical solution of the main Fokker-Planck model for various sets of parameters (γ,p). Left: Surface and contour plot of the distribution function f(r,μ). The truncation at r=2 and μ=2 is only for visualization purposes. Right: Corresponding marginal density ρ compared with ρfast and ρ0.

    In order to confirm that the main Fokker-Planck model reduces the coefficient of variation as soon as γ>0 we draw on Figure 4 the coefficient of variation for each distribution ρ,ρfast relatively to that of ρ0 for several values of p. We observe that indeed, the coefficient of variation is reduced. As in the case of fast μRNA, the decay is more pronounced when the production of μRNA is higher than that of mRNA, namely when p>1. Interestingly enough, one also notices that the approximation ρfast increases the reduction of CV when p>1 and diminishes it when p<1. A transition at the special value p=1 was already observed on Figure 1.

    Figure 4.  Numerical results. Relative coefficient of variation versus γ for various values of p.

    In this section, we discuss the influence of the type of noise in the Fokker-Planck models. Let us go back to the system of stochastic differential equations considered at the beginning and generalize it as follows

    {drt=(crcrtμtkrrt)dt+ 2σrD(rt)dB1t,dμt=(cμcrtμtkμμt)dt+2σμD(μt)dB2t,

    with D some given function. In the models of the previous sections we chose D(x)=x2. On the one hand it is natural to impose that D(x) vanishes when x0 in order to preserve the non-negativity of rt and μt. On the other hand it is clear that the growth at infinity influences the tail of the equilibrium distribution which solves the corresponding Fokker-Planck equation. With a quadratic D we obtained algebraically decaying distributions.

    Nevertheless one may wonder if the decay of cell to cell variation due to μRNA would still be observed if D is changed so that it involves distributions with faster decay at infinity. In order to answer this question, we choose a simple enough function D so that we can still derive analytical formulas for distributions of mRNA without binding and mRNA in the presence of "fast" μRNA. Let us assume that

    D(r)=r.

    In terms of modeling we may argue as in Section 2 and Section 3 in order to introduce the stationary probability distribution of mRNA without binding ˜ρ0 which solves

    r[σrr(r˜ρ0)(crkrr)˜ρ0] = 0.

    It may still be solved analytically and one finds a gamma distribution

    ˜ρ0(r) = γcrσr,krσr(r) = Ccrσr,krσrrcrσr1ekrσrr (6.1)

    instead of an inverse gamma distribution in the quadratic case. The normalization constant is given in Section 3.1.

    In the case of fast μRNA, we may once again follow the method of Section 2 and Section 3 and introduce ˜ρfast solving

    r[r(σr r ˜ρfast)( crc r ˜jfast(r)kr r)˜ρfast] = 0

    where the conditional expectation of the number of μRNA within the population with r mRNA is given by

    ˜jfast(r) = 0μγcμσμ,kμ+crσμ(μ)dμ = cμkμ+cr.

    A direct computation then yields

    ˜ρfast(r) = C(1+ckμr)cμσrrcrσr1ekrσrr, (6.2)

    with CC(cr,cμ,c,kr,kμ,σr,σμ) a normalizing constant.

    Remark 6.1. Observe that the conditional expectation of the number of μRNA within the population with r mRNA is unchanged, namely ˜jfast(r)=jfast(r). More generally, the expectation of a univariate process (Xt)t satisfying an SDE with linear drift dXt=(a+bXt)dt+2σ(Xt)dBt does not depend on the diffusion coefficient σ as its density g satisfy tg(t,x)+x((a+bx)g(t,x))2xx(σ(x)g(t,x))=0, so that multiplying by x and integrating yields dE[Xt]=(a+bE[Xt])dt on its expectation E[Xt]. The argument also holds for multivariate processes.

    Once again we seek the parameters of importance among the many parameters of the model by a dimensional analysis. The characteristic value of r remains ˉr=cr/kr as it is the expectation of ˜ρ0. After rescaling we find the new distribution

    ˜ρη0(r) = γη,η(r) = Cη,ηrη1eηr, (6.3)

    and

    ˜ρfastη,γ,p(r) = Cadfastrη1(1+γr)pηeηr. (6.4)

    where the parameters p and γ are given by Eqs (4.7) and (4.6) respectively and still quantify the intensity of the binding and the respective production of μRNA versus mRNA. The new parameter η is given by

    η = crσr. (6.5)

    In the context of a dimensional analysis, let us mention that it would be inaccurate to compare η and δ as the σr (and σμ) do not represent the same quantity depending on the choice of D. For D(r)=r2 it has the same dimension as kr so δ=kr/σr is the right dimensionless parameter. Here it has the same dimension as cr, which justifies the introduction of η.

    The expectation, variance and coefficient of variation of ˜ρ0 are explicitly given by

    Exp(˜ρη0) = 1,Var(˜ρη0) = 1η,CV(˜ρη0) = 1η, (6.6)

    As there is no explicit formula for the coefficient of variation of ˜ρfastη,γ,p we evaluate it numerically as in Section 4.3. The results are displayed on Figure 5. We observe that unlike the case of a quadratic diffusion coefficient the relative cell to cell variation, i.e., the cell to cell variation in the presence of μRNA relative to cell to cell variations of the free case, is not unconditionally less than 1. For a large enough production of μRNA, it eventually decays when the binding effect is very strong. However for smaller production of μRNA or when the binding is weak, the effect is the opposite as the relative cell to cell variation is greater than 1. This is not satisfactory from the modeling point of view.

    Figure 5.  {Numerical computation of the cell to cell variation.} Relative cell to cell variation CV(˜ρfastη,γ,p)/CV(ρη0) for various parameters p, γ and η. On the horizontal axis, left means more production of mRNA and right means more production of μRNA; On the vertical axis, top means more destruction of mRNA by binding and bottom means more destruction/consumption of mRNA by other mechanisms.

    In conclusion the choice of noise is important in this model. An unconditional cell to cell variation decay in the presence of μRNA is observed for quadratic noise only. While other choices of noise may still lead to similar qualitative results, the choice D(r)=r2 allowed us to derive explicit formulas for the approximate density ρfast which, as numerical simulations show, is fairly close to the marginal ρ corresponding to the solution of the main Fokker-Planck model.

    In this paper, we introduced a new model describing the joint probability density of the number of mRNA and μRNA in a cell. It is based on a Fokker-Planck equation arising from a system of chemical kinetic equations for the number of two RNAs. The purpose of this simple model was to provide a mathematical framework to investigate how robustness in gene expression in a cell is affected by the presence of a regulatory feed-forward loop due to production of μRNAs which bind to and deactivate mRNAs.

    Thanks to the combined use of analytical formulas and numerical simulations, we showed that robustness of gene expression is indeed affected by the presence of a feed-forward loop involving μRNA production. However, whether the effect is regulatory or de-regulatory strongly depends on the assumptions made on the type of noise affecting both mRNA and μRNAs production. In the case of geometric noise (the diffusivity being quadratic in the solution itself), the effect is to reduce the spread of the distribution as the reduction of the coefficient of variation shows. In the case of sub-geometric noise (the diffusivity being only linear in the solution itself), the effect increases the spread as shown by the increase of the coefficient of variation. We may attempt an explanation by comparing the mRNA distribution in the absence of μRNA and in the limit of fast μRNA in the two cases. In the quadratic diffusivity case, both distributions are fat-tailed (i.e., they decay polynomially with the number of unbound mRNA molecules r, see Eqs (3.6) and (3.9)) but the rate of decay at infinity is modified by the presence of μRNAs. On the other hand, in the linear diffusivity case, both decay exponentially fast (see Eqs (6.1) and (6.2)) and the exponential rate of decay is the same with or without μRNAs. We propose that this might be the reason of the difference: In the quadratic diffusivity case, the change in polynomial decay allows to greatly reduce the standard deviation without affecting too much the mean, which results in a reduction of the coefficient of variation. In the linear diffusivity case, the exponential tail is not modified, which implies that the core of the distribution must be globally translated towards the origin, which affects the mean and the standard deviation in a similar way and does not systematically reduce the coefficient of variation. Which type of noise corresponds to the actual data is unknown at this stage. While quadratic diffusivity seems a fairly reasonable assumption (it is used in a number of contexts such as finance), it would require further experimental investigations to be fully justified in the present context. This discussion shows that the effect of μRNA on noise regulation of mRNA translation is subtle and not easily predictable.

    Along the way we provided theoretical tools for the analysis of the Fokker Planck equation at play and robust numerical methods for simulations. As the main biological hypothesis for the usefulness of μRNA in the regulation of gene expression is based on their ability to reduce external noise, we also discussed the particular choice of stochasticity in the model.

    There are several perspectives to this work. A first one would be the calibration of the parameters of the model from real-world data. This would allow to quantify more precisely the amount of cell-to-cell variation reduction due to μRNA, thanks to the thorough numerical investigation done in this contribution of the effects of the parameters of the model. Besides, another perspective would be an improvement of inequality (4.12) to the conjecture (4.3). This would bring a definitive theoretical answer to the hypothesis of increased gene expression level in the simplified model of "fast" μRNAs. One may also look into establishing a similar inequality for the general model. Finally, the gene regulatory network in a cell is considerably more complex than the simple, yet enlightening in our opinion, dynamics proposed in this paper. A natural improvement would be the consideration of more effects in the model, such as the production of the transcription factor, or the translation of mRNA into proteins, among many others.

    PD acknowledges support by the Engineering and Physical Sciences Research Council (EPSRC) under grants no. EP/M006883/1 and EP/N014529/1, by the Royal Society and the Wolfson Foundation through a Royal Society Wolfson Research Merit Award no. WM130048 and by the National Science Foundation (NSF) under grant no. RNMS11-07444 (KI-Net). PD is on leave from CNRS, Institut de Mathématiques de Toulouse, France. MH acknowledges support by the Labex CEMPI (ANR-11-LABX-0007-01). SM acknowledges support by the CNRS–Royal Society exchange projects "CODYN" and "Segregation models in social sciences" and the Chaire Modélisation Mathématique et Biodiversité of Véolia Environment - École Polytechnique - Museum National d’Histoire Naturelle - Fondation X. All authors would like to thank Prof. Matthias Merkenshlager from Imperial College Institute of Clinical Sciences for bringing this problem to their attention and stimulating discussions.

    The authors declare no conflict of interest.

    No new data were collected in the course of this research.

    In this section we give a elementary proof of the 1D version of the Brascamp and Lieb inequality (see [23,Theorem 4.1], [24]), which is an extension of the Gaussian Poincaré inequality in the case of log-concave measures. This allows us to derive a weighted Poincaré inequality for the gamma distribution and deduce, by a change of variable, a similar functional inequality for the inverse gamma distribution.

    Proposition A.1. Let IR be an open non-empty interval and V:IR a function of class C2. Assume that

    (i) V is strictly convex;

    (ii) eV is a probability density on I;

    (iii) V tends to + at the extremities of I.

    Then, for any suitably integrable function u, one has

    I|u(x)ueV|2eV(x)dx  I|u(x)|2eV(x)(V"(x))1dx, (A.1)

    where for a density ν the notation uν denotes uν.

    Proof. Without loss of generality, as one may replace u with uueV, we assume that ueV=0. We also assume that u is of class C1 and compactly supported in I and one can then extend a posteriori the class of admissible function by a standard density argument. Then, using (ii) one has

    I|u(x)|2eV(x)dx=12I×I|u(x)u(y)|2e(V(x)+V(y))dxdy=12I×I|yxu(z)dz|2e(V(x)+V(y))dxdy.

    Now using the Cauchy-Schwarz inequality and assumption (i) one has

    I|u(x)|2eV(x)dx 12I×I(yx|u(z)|2(V"(z))1dz)(yxV"(z)dz)e(V(x)+V(y))dxdy.

    Then take any point x0I and define

    U(x)=xx0|u(z)|2(V"(z))1dz,

    so that the inequality rewrites

    I|u(x)|2eV(x)dx12I×I(U(y)U(x))(V(y)V(x))e(V(x)+V(y))dxdy.

    Now just expand the right-hand side and use Fubini's theorem on each term as well as assumptions (ii) and (iii) to obtain

    I|u(x)|2eV(x)dx  IU(x)V(x)eV(x)dx.

    One concludes by integrating the right-hand side by parts and observing that boundary terms vanish again by assumption (iii).

    Remark A.2. The proof is an adaptation of the original proof of the (flat) Poincaré-Wirtinger inequality by Poincaré.

    Observe that for I=R and V(x)=x2/2, one recovers the classical Gaussian Poincaré inequality.

    Remark A.3. The inequality is sharp. It is an equality for functions of the form u(x)=aV(x)+b, with a,bR if V is such that V(x)eV(x) tends to 0 at the boundaries, and only for constant functions otherwise (i.e., a=0 and bR).

    From the Brascamp-Lieb inequality, we now infer Poincaré inequalities for gamma and inverse gamma distributions.

    Proposition A.4. Let α>1 and β>0. Then, for any functions u,v such that the integrals make sense, one has

    0|u(x)uγα,β|2γα,β(x)dx  1α10|u(x)|2γα,β(x)x2dx, (A.2)

    and

    0|v(y)vgα,β|2gα,β(y)dy  1α10|v(y)|2gα,β(y)y2dy, (A.3)

    where for a probability density ν the notation uν denotes uν.

    Proof. The first inequality is an application of Eq (A.1) with V(x)=βx(α1)ln(x)ln(Cα,β), where Cα,β=βα/Γ(α). Then take v(y)=u(1/y) and make the change of variable y=1/x in all the integrals of Eq (A.2) to get the result.

    Remark A.5. To the best of our knowledge the classical Bakry and Emery method does not seem to apply to show directly the functional inequalities of Proposition A.4. Let us give some details. In order to show a Poincaré inequality of the type

    I|u(x)ueV|2eV(x)dx  I|u(x)|2eV(x)D(x)dx,

    for V as in Proposition A.1, it is sufficient that D and V satisfy the following curvature-dimension inequality

    R(x) := 14(D(x))212D"(x)D(x)+D(x)2V"(x)+12D(x)D(x)V(x)  λ1D(x), (A.4)

    for some positive constant λ1>0. We refer to [25,26] for the general form of the latter Bakry-Emery condition (for multidimensional anisotropic inhomogeneous diffusions) and to [27] or [28] for the simpler expression in the case of isotropic inhomogeneous diffusion, as discussed here. In the case of the inequalities (A.2) and (A.3), one has respectively D(x)=x2/(α1), V(x)=βx(α1)ln(x)ln(Cα,β) and D(y)=y2/(α1), V(y)=β/y+(α+1)ln(y)ln(Cα,β), which yields respectively R(x)=βx3/(α1)2 and R(y)=βy/(α1)2. As claimed above, neither Eq (A.2) nor Eq (A.3) satisfy the condition (A.4). One also observes that in both cases the curvature-dimension inequality fails because of a degeneracy at one end of the interval.

    Let us finally mention that there are in the literature other occurrences of Poincaré and more generally convex Sobolev inequalities for gamma distributions [29,30,31,32]. However, we found out that the diffusion coefficient is always taken of the form D(x)=4x/β. This weight, associated with the gamma invariant measure, corresponds to the Laguerre diffusion Lα,βf(x)=βxf"(βx)(αβx)f(βx). This operator differs from the adjoint of the one appearing in our model given by Eq (2.6). In this case, one can check that the curvature-dimension condition of Bakry and Emery is satisfied as soon as α1/2.

    Proposition A.6. One has the bound

    CV(ρδ,γ,pfast)  Cδ := ((δδ1)2(11(δ1)2)δ21)12,

    which holds for all δ>2, γ>0 and p0.

    Proof. The bound is a consequence of the Prékopa-Leindler inequality (see [23] and references therein) which states that if f,g,h:Rd[0,+) are three functions satisfying for some λ(0,1) and for all x,y,

    h((1λ)x+λy)f(x)1λg(y)λ, (A.5)

    then

    hL1(Rd)  f1λL1(Rd)gλL1(Rd). (A.6)

    We use it with λ=1/2, f(x)=(1+x)γpδxδ2eδγx if x0 and f(x)=0 if x<0, g(x)=x2f(x) and h(x)=(1+C2δ)1/2xf(x). The condition (A.5) is then equivalent to

    (1+C2δ)1/2  [(1+x+y2)(1+x)(1+y)]γpδ2(yx)12((yx)12+(xy)122)δ1

    which is satisfied as the term between brackets is always greater than 1 and the function zz[(z+z1)/2]δ1, z>0 is bounded from below by (1+C2δ)1/2, where Cδ is given in Eq (4.12). Then with the change of variable x=1/(γx) in the integrals of Eq (A.6), one recovers Eq (4.12).

    [1] Kultz D (2005) Molecular and evolutionary basis of the cellular stress response. Annu Rev Physiol 67: 225-257. doi: 10.1146/annurev.physiol.67.040403.103635
    [2] Nassif M, Matus S, Castillo K, et al. (2010) Amyotrophic lateral sclerosis pathogenesis: a journey through the secretory pathway. Antioxid Redox Sign 13: 1955-1989. doi: 10.1089/ars.2009.2991
    [3] Schapira AH, Olanow CW, Greenamyre JT, et al. (2014) Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 384: 545-555.
    [4] Massano J, Bhatia KP (2012) Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harbor Perspect Med 2: a008870.
    [5] Chaudhuri KR, Odin P, Antonini A, et al. (2011) Parkinson's disease: the non-motor issues. Parkinsonism Relat D 17: 717-723. doi: 10.1016/j.parkreldis.2011.02.018
    [6] Greenamyre JT, Hastings TG (2004) Biomedicine. Parkinson's--divergent causes, convergent mechanisms. Science 304: 1120-1122.
    [7] Spillantini MG, Schmidt ML, Lee VM, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
    [8] Baba M, Nakajo S, Tu PH, et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152: 879-884.
    [9] Cox D, Carver JA, Ecroyd H (2014) Preventing alpha-synuclein aggregation: the role of the small heat-shock molecular chaperone proteins. BBA 1842: 1830-1843.
    [10] Bonifati V, Rizzu P, van Baren MJ, et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259.
    [11] Andersson FI, Werrell EF, McMorran L, et al. (2011) The effect of Parkinson's-disease-associated mutations on the deubiquitinating enzyme UCH-L1. J Mol Biol 407: 261-272. doi: 10.1016/j.jmb.2010.12.029
    [12] Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909. doi: 10.1016/S0896-6273(03)00568-3
    [13] Dawson TM, Dawson VL (2010) The role of parkin in familial and sporadic Parkinson's disease. Movement Disord 25: S32-39. doi: 10.1002/mds.22798
    [14] Sidransky E, Lopez G (2012) The link between the GBA gene and parkinsonism. Lancet Neurol 11: 986-998.
    [15] Al-Chalabi A, Jones A, Troakes C, et al. (2012) The genetics and neuropathology of amyotrophic lateral sclerosis. Acta neuropathol 124: 339-352.
    [16] Rosen DR, Siddique T, Patterson D, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62. doi: 10.1038/362059a0
    [17] Neumann M, Sampathu DM, Kwong LK, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130-133.
    [18] Arai T, Hasegawa M, Akiyama H, et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351: 602-611. doi: 10.1016/j.bbrc.2006.10.093
    [19] Deng HX, Zhai H, Bigio EH, et al. (2010) FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Annals Neurol 67: 739-748.
    [20] Nishimura AL, Mitne-Neto M, Silva HC, et al. (2004) A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75: 822-831.
    [21] Parkinson N, Ince PG, Smith MO, et al. (2006) ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 67: 1074-1077. doi: 10.1212/01.wnl.0000231510.89311.8b
    [22] Deng HX, Chen W, Hong ST, et al. (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477: 211-215. doi: 10.1038/nature10353
    [23] Johnson JO, Mandrioli J, Benatar M, et al. (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68: 857-864. doi: 10.1016/j.neuron.2010.11.036
    [24] Maruyama H, Morino H, Ito H, et al. (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465: 223-226. doi: 10.1038/nature08971
    [25] Fecto F, Yan J, Vemula SP, et al. (2011) SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 68:1440-1446. doi: 10.1001/archneurol.2011.250
    [26] Rubino E, Rainero I, Chio A, et al. (2012) SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 79: 1556-1562. doi: 10.1212/WNL.0b013e31826e25df
    [27] Teyssou E, Takeda T, Lebon V, et al. (2013) Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. Acta Neuropathol 125: 511-522. doi: 10.1007/s00401-013-1090-0
    [28] Li J, Li W, Jiang ZG, et al. (2013) Oxidative stress and neurodegenerative disorders. Int J Mol Sci 14: 24438-24475. doi: 10.3390/ijms141224438
    [29] Ayala A, Munoz MF, Arguelles S (2014) Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Med Cell Longev: 360438.
    [30] Gandhi S, Abramov AY (2012) Mechanism of oxidative stress in neurodegeneration. Oxidative Med Cell Longev: 428010.
    [31] Halliwell B (2001) Role of free radicals in the neurodegenerative diseases. Drug Aging 18: 685-716 doi: 10.2165/00002512-200118090-00004
    [32] Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97: 1634-1658. doi: 10.1111/j.1471-4159.2006.03907.x
    [33] Milani P, Ambrosi G, Gammoh O, et al. (2013) SOD1 and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegeneration. Oxidative Med Cell Longev:836760.
    [34] Parakh S, Spencer DM, Halloran MA, et al. (2013) Redox regulation in amyotrophic lateral sclerosis. Oxidative Med Cell Longev: 408681.
    [35] Streck EL, Czapski GA, Goncalves et al. (2013) Neurodegeneration, mitochondrial dysfunction, and oxidative stress. Oxidative Med Cell Longev: 826046.
    [36] Varcin M, Bentea E, Michotte Y, et al. (2012) Oxidative stress in genetic mouse models of Parkinson's disease. Oxidative Med Cell Longev: 624925.
    [37] Navarro A, Boveris A, Bandez MJ, et al. (2009) Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radical Biol Med 46: 1574-1580. doi: 10.1016/j.freeradbiomed.2009.03.007
    [38] Alam ZI, Jenner A, Daniel SE, et al. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196-1203.
    [39] Abe T, Isobe C, Murata T, et al. (2003) Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci Lett 336: 105-108. doi: 10.1016/S0304-3940(02)01259-4
    [40] Kikuchi A, Takeda A, Onodera H, et al. (2002) Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 9: 244-248. doi: 10.1006/nbdi.2002.0466
    [41] Isobe C, Abe T, Terayama Y (2010) Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci Lett 469: 159-163. doi: 10.1016/j.neulet.2009.11.065
    [42] Nikam S, Nikam P, Ahaley SK, et al. (2009) Oxidative stress in Parkinson's disease. Indian J Clin Biochem 24: 98-101. doi: 10.1007/s12291-009-0017-y
    [43] Barber SC, Mead RJ, Shaw PJ (2006) Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 1762: 1051-1067. doi: 10.1016/j.bbadis.2006.03.008
    [44] Barber SC, Shaw PJ (2010) Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radical Boil Med 48: 629-641. doi: 10.1016/j.freeradbiomed.2009.11.018
    [45] Ferrante RJ, Browne SE, Shinobu LA, et al. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69: 2064-2074.
    [46] Cutler RG, Pedersen WA, Camandola S (2002) Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 52: 448-457. doi: 10.1002/ana.10312
    [47] Pedersen WA, Fu W, Keller JN, et al. (1998) Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 44: 819-824.
    [48] Abe K, Pan LH, Watanabe M, et al. (1995) Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett 199: 152-154. doi: 10.1016/0304-3940(95)12039-7
    [49] Beal MF, Ferrante RJ, Browne SE, et al. (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42: 644-654. doi: 10.1002/ana.410420416
    [50] Shaw PJ, Ince PG, Falkous G, et al. (1995) Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 38: 691-695. doi: 10.1002/ana.410380424
    [51] Fitzmaurice PS, Shaw IC, Kleiner HE, et al. (1996) Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve 19: 797-798.
    [52] Said Ahmed M, Hung WY, Zu JS, et al. (2000) Increased reactive oxygen species in familial amyotrophic lateral sclerosis with mutations in SOD1. J neurol Sci 176: 88-94. doi: 10.1016/S0022-510X(00)00317-8
    [53] Milani P, Amadio M, Laforenza U, et al. (2013) Posttranscriptional regulation of SOD1 gene expression under oxidative stress: Potential role of ELAV proteins in sporadic ALS. Neurobiol Dis 60: 51-60.
    [54] Cereda C, Leoni E, Milani P, et al. (2013) Altered intracellular localization of SOD1 in leukocytes from patients with sporadic amyotrophic lateral sclerosis. PlOS One 8: e75916. doi: 10.1371/journal.pone.0075916
    [55] Smith RG, Henry YK, Mattson MP, et al. (1998) Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 44: 696-699. doi: 10.1002/ana.410440419
    [56] Ihara Y, Nobukuni K, Takata H, et al. (2005) Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res 27: 105-108. doi: 10.1179/016164105X18430
    [57] Kirby J, Halligan E, Baptista MJ, et al. (2005) Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain 128: 1686-1706.
    [58] Mimoto T, Miyazaki K, Morimoto N, et al. (2012) Impaired antioxydative Keap1/Nrf2 system and the downstream stress protein responses in the motor neuron of ALS model mice. Brain Res 1446: 109-118. doi: 10.1016/j.brainres.2011.12.064
    [59] Petri S, Korner S, Kiaei M (2012) Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS. Neurol Res Int: 878030.
    [60] Sarlette A, Krampfl K, Grothe C, et al. (2008) Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J Neuropath Exp Neurol 67: 1055-1062. doi: 10.1097/NEN.0b013e31818b4906
    [61] Cao SS, Kaufman RJ (2014) Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid Redox Signaling 21: 396-413. doi: 10.1089/ars.2014.5851
    [62] Begum G, Harvey L, Dixon CE, et al. (2013) ER stress and effects of DHA as an ER stress inhibitor. Translational Stroke Res 4: 635-642. doi: 10.1007/s12975-013-0282-1
    [63] Bellucci A, Navarria L, Zaltieri M, et al. (2011) Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease. J Neurochem 116: 588-605. doi: 10.1111/j.1471-4159.2010.07143.x
    [64] Colla E, Jensen PH, Pletnikova O, et al. (2012) Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J Neurosci 32: 3301-3305. doi: 10.1523/JNEUROSCI.5368-11.2012
    [65] Nishitoh H, Kadowaki H, Nagai A, et al. (2008) ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev 22: 1451-1464. doi: 10.1101/gad.1640108
    [66] Atkin JD, Farg MA, Soo KY, et al. (2014) Mutant SOD1 inhibits ER-Golgi transport in amyotrophic lateral sclerosis. J Neurochem 129: 190-204. doi: 10.1111/jnc.12493
    [67] Hetz C, Mollereau B (2014) Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci 15: 233-249.
    [68] Mercado G, Valdes P, Hetz C (2013) An ERcentric view of Parkinson's disease. Trends Mol Med 19: 165-175. doi: 10.1016/j.molmed.2012.12.005
    [69] Hoozemans JJ, van Haastert ES, Eikelenboom P, et al. (2007) Activation of the unfolded protein response in Parkinson's disease. Biochem Bioph Res Commun 354: 707-711. doi: 10.1016/j.bbrc.2007.01.043
    [70] Slodzinski H, Moran LB, Michael GJ, et al. (2009) Homocysteine-induced endoplasmic reticulum protein (herp) is up-regulated in parkinsonian substantia nigra and present in the core of Lewy bodies. Clin Neuropathol 28: 333-343.
    [71] Holtz WA, Turetzky JM, Jong YJ, et al. (2006) Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. J Neurochem 99: 54-69. doi: 10.1111/j.1471-4159.2006.04025.x
    [72] Dukes AA, Van Laar VS, Cascio M, et al. (2008) Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine. J Neurochem 106: 333-346. doi: 10.1111/j.1471-4159.2008.05392.x
    [73] Tinsley RB, Bye CR, Parish CL, et al. (2009) Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol 66: 472-484. doi: 10.1002/ana.21716
    [74] Mercado G, Castillo V, Soto P, et al. (2016) ER stress and Parkinson's disease: Pathological inputs that converge into the secretory pathway. Brain Res 1648: 626-632. doi: 10.1016/j.brainres.2016.04.042
    [75] Walker AK, Atkin JD (2011) Stress signaling from the endoplasmic reticulum: A central player in the pathogenesis of amyotrophic lateral sclerosis. IUBMB Life 63: 754-763.
    [76] Hetz C, Thielen P, Matus S, et al. (2009) XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev 23: 2294-2306. doi: 10.1101/gad.1830709
    [77] Wang L, Popko B, Roos RP (2014) An enhanced integrated stress response ameliorates mutant SOD1-induced ALS. Hum Mol Genet 23: 2629-2638. doi: 10.1093/hmg/ddt658
    [78] Carreras-Sureda A, Pihan P, Hetz C (2017) The Unfolded Protein Response: At the Intersection between Endoplasmic Reticulum Function and Mitochondrial Bioenergetics. Front Oncol 7: 55.
    [79] Erpapazoglou Z, Mouton-Liger F, Corti O (2017) From dysfunctional endoplasmic reticulum-mitochondria coupling to neurodegeneration. Neurochem Int.
    [80] Eletto D, Chevet E, Argon Y, et al. (2014) Redox controls UPR to control redox. J Cell Sci 127: 3649-3658. doi: 10.1242/jcs.153643
    [81] Zhang K, Kaufman RJ (2008) From endoplasmic-reticulum stress to the inflammatory response. Nature 454: 455-462.
    [82] Tu BP, Weissman JS (2004) Oxidative protein folding in eukaryotes: mechanisms and consequences. J Cell Biol 164: 341-346. doi: 10.1083/jcb.200311055
    [83] Cuozzo JW, Kaiser CA (1999) Competition between glutathione and protein thiols for disulphide-bond formation. Nat Cell Biol 1: 130-135. doi: 10.1038/11047
    [84] Perri E, Parakh S, Atkin J (2017) Protein Disulphide Isomerases: emerging roles of PDI and ERp57 in the nervous system and as therapeutic targets for ALS. Exp Opin Targets 21: 37-49. doi: 10.1080/14728222.2016.1254197
    [85] Perri ER, Thomas CJ, Parakh S, et al. (2015) The Unfolded Protein Response and the Role of Protein Disulfide Isomerase in Neurodegeneration. Front Cell Dev Biol 3: 80.
    [86] Chaudhari N, Talwar P, Parimisetty A, et al. (2014) A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. Front Cell Neurosci 8: 213.
    [87] Chiribau CB, Gaccioli F, Huang CC, et al. (2010) Molecular symbiosis of CHOP and C/EBP beta isoform LIP contributes to endoplasmic reticulum stress-induced apoptosis. Mol Cell Biol 30: 3722-3731. doi: 10.1128/MCB.01507-09
    [88] Yamaguchi H, Wang HG (2004) CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 279: 45495-45502. doi: 10.1074/jbc.M406933200
    [89] Lu M, Lawrence DA, Marsters S, et al. (2014) Cell death. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science 345: 98-101.
    [90] Li G, Mongillo M, Chin KT, et al (2009) Role of ERO1-alpha-mediated stimulation of inositol 1,4,5-triphosphate receptor activity in endoplasmic reticulum stress-induced apoptosis. J Cell biol 186: 783-792.
    [91] Marciniak SJ, Yun CY, Oyadomari S, et al. (2004) CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Gene Dev 18: 3066-3077. doi: 10.1101/gad.1250704
    [92] Chen G, Bower KA, Ma C, et al. (2004) Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 18: 1162-1164.
    [93] McNeill A, Magalhaes J, Shen C, et al. (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137: 1481-1495.
    [94] Prell T, Lautenschlager J, Weidemann L, et al. (2014) Endoplasmic reticulum stress is accompanied by activation of NF-kappaB in amyotrophic lateral sclerosis. J Neuroimmunol 270: 29-36. doi: 10.1016/j.jneuroim.2014.03.005
    [95] Yang W, Tiffany-Castiglioni E, Koh HC, et al. (2009) Paraquat activates the IRE1/ASK1/JNK cascade associated with apoptosis in human neuroblastoma SH-SY5Y cells. Toxicol Lett 191: 203-210. doi: 10.1016/j.toxlet.2009.08.024
    [96] Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37-40. doi: 10.1038/35065000
    [97] Darling NJ, Cook SJ (2014) The role of MAPK signalling pathways in the response to endoplasmic reticulum stress. BBA 1843: 2150-2163.
    [98] Davis RJ (2000): Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
    [99] Abais JM, Xia M, Zhang Y, et al. (2014) Redox Regulation of NLRP3 Inflammasomes: ROS as Trigger or Effector? Antioxid Redox Signaling 22: 1111-1129.
    [100] Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32: 577-595. doi: 10.1007/s11064-006-9128-5
    [101] Nijholt DA, Nolle A, van Haastert ES, et al. (2013) Unfolded protein response activates glycogen synthase kinase-3 via selective lysosomal degradation. Neurobiol Aging 34: 1759-1771. doi: 10.1016/j.neurobiolaging.2013.01.008
    [102] Meares GP, Mines MA, Beurel E, et al. (2011) Glycogen synthase kinase-3 regulates endoplasmic reticulum (ER) stress-induced CHOP expression in neuronal cells. Exp Cell Res 317: 1621-1628. doi: 10.1016/j.yexcr.2011.02.012
    [103] Giordano S, Darley-Usmar V, Zhang J (2014) Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol 2: 82-90. doi: 10.1016/j.redox.2013.12.013
    [104] Loos B, Engelbrecht AM, Lockshin RA, et al. (2013) The variability of autophagy and cell death susceptibility: Unanswered questions. Autophagy 9: 1270-1285. doi: 10.4161/auto.25560
    [105] Scheper W, Nijholt DA, Hoozemans JJ (2011) The unfolded protein response and proteostasis in Alzheimer disease: preferential activation of autophagy by endoplasmic reticulum stress. Autophagy 7: 910-911. doi: 10.4161/auto.7.8.15761
    [106] Deegan S, Saveljeva S, Logue SE, et al. (2014) Deficiency in the mitochondrial apoptotic pathway reveals the toxic potential of autophagy under ER stress conditions. Autophagy 10: 1921-1936. doi: 10.4161/15548627.2014.981790
    [107] Madeo F, Eisenberg T, Kroemer G (2009) Autophagy for the avoidance of neurodegeneration. Gene Dev 23: 2253-2259. doi: 10.1101/gad.1858009
    [108] Cai Y, Arikkath J, Yang L, et al. (2016) Interplay of endoplasmic reticulum stress and autophagy in neurodegenerative disorders. Autophagy 12: 225-244.
    [109] Cortes CJ, Miranda HC, Frankowski H, et al. (2014) Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. Nat Neurosci 17: 1180-1189. doi: 10.1038/nn.3787
    [110] Palmieri M, Impey S, Kang H, et al. (2011) Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum Mol Genet 20: 3852-3866. doi: 10.1093/hmg/ddr306
    [111] Brehme M, Voisine C, Rolland T, et al. (2014) A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep 9: 1135-1150. doi: 10.1016/j.celrep.2014.09.042
    [112] Genereux JC, Qu S, Zhou M, et al. (2014) Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis. EMBO J.
    [113] Montane J, Cadavez L, Novials A (2014) Stress and the inflammatory process: a major cause of pancreatic cell death in type 2 diabetes. Diabetes, metab syndrome obesity: targets ther 7: 25-34.
    [114] Song W, Wang F, Savini M, et al. (2013) TFEB regulates lysosomal proteostasis. Hum Mol Genet 22: 1994-2009.
    [115] Tan YL, Genereux JC, Pankow S, et al. (2014) ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease. Chem Biol 21: 967-976. doi: 10.1016/j.chembiol.2014.06.008
    [116] Wei H, Kim SJ, Zhang Z, et al. (2008) ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum Mol Genet 17: 469-477.
    [117] Sybertz E, Krainc D (2014) Development of targeted therapies for Parkinson's disease and related synucleinopathies. J Lipid Res 55: 1996-2003. doi: 10.1194/jlr.R047381
    [118] Duplan E, Giaime E, Viotti J, et al. (2013) ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1. J Cell Sci 126: 2124-2133. doi: 10.1242/jcs.127340
    [119] Yokota T, Sugawara K, Ito K, et al. (2003) Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 312: 1342-1348. doi: 10.1016/j.bbrc.2003.11.056
    [120] Sajjad MU, Green EW, Miller-Fleming L, et al. (2014) DJ-1 modulates aggregation and pathogenesis in models of Huntington's disease. Hum Mol Genet 23: 755-766.
    [121] Shendelman S, Jonason A, Martinat C, et al. (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLOS Biol 2: e362. doi: 10.1371/journal.pbio.0020362
    [122] Jarvela TS, Lam HA, Helwig M, et al. (2016) The neural chaperone proSAAS blocks alpha-synuclein fibrillation and neurotoxicity. P Natl Acad Sci UAS 113: E4708-4715. doi: 10.1073/pnas.1601091113
    [123] Carra S, Rusmini P, Crippa V, et al. (2013) Different anti-aggregation and pro-degradative functions of the members of the mammalian sHSP family in neurological disorders. Phil Trans R Soc B 368: 20110409.
    [124] Chaari A, Hoarau-Vechot J, Ladjimi M (2013) Applying chaperones to protein-misfolding disorders: molecular chaperones against alpha-synuclein in Parkinson's disease. Int J Boil macromolecules 60: 196-205. doi: 10.1016/j.ijbiomac.2013.05.032
    [125] Fontaine SN, Martin MD, Dickey CA (2016) Neurodegeneration and the Heat Shock Protein 70 Machinery: Implications for Therapeutic Development. Curr Top Med Chem 16: 2741-2752. doi: 10.2174/1568026616666160413140741
    [126] Lindberg I, Shorter J, Wiseman RL (2015) Chaperones in Neurodegeneration. J Neurosci 35: 13853-13859. doi: 10.1523/JNEUROSCI.2600-15.2015
    [127] Chen S, Brown IR (2007) Neuronal expression of constitutive heat shock proteins: implications for neurodegenerative diseases. Cell Stress Chaperon 12: 51-58. doi: 10.1379/CSC-236R.1
    [128] Galbiati M, Crippa V, Rusmini P, et al. (2014) ALS-related misfolded protein management in motor neurons and muscle cells. Neurochem Int 79: 70-78. doi: 10.1016/j.neuint.2014.10.007
    [129] Papsdorf K, Richter K (2014) Protein folding, misfolding and quality control: the role of molecular chaperones. Essays Biochem 56: 53-68. doi: 10.1042/bse0560053
    [130] Baluchnejadmojarad T, Roghani M, Nadoushan MR, et al. (2009) Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model. Phytother Res 23: 132-135. doi: 10.1002/ptr.2564
    [131] Choi BS, Kim H, Lee HJ, et al. (2014) Celastrol from 'Thunder God Vine' protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson's disease. Neurochem Res 39: 84-96. doi: 10.1007/s11064-013-1193-y
    [132] Inden M, Kitamura Y, Takeuchi H, et al. (2007) Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 101: 1491-1504. doi: 10.1111/j.1471-4159.2006.04440.x
    [133] Jiang HQ, Ren M, Jiang HZ, et al. (2014) Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neurosci 277: 132-138.
    [134] Mortiboys H, Aasly J, Bandmann O (2013) Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain 136: 3038-3050.
    [135] Ono K, Ikemoto M, Kawarabayashi T, et al. (2009) A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. Parkinsonism Relat D 15: 649-654.
    [136] Ozsoy O, Seval-Celik Y, Hacioglu G, et al. (2011) The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease. Neurochem Int 59: 664-670. doi: 10.1016/j.neuint.2011.06.012
    [137] Richter F, Fleming SM, Watson M, et al. (2014) A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics 11: 840-856. doi: 10.1007/s13311-014-0294-x
    [138] Saxena S, Cabuy E, Caroni P (2009) A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nature Neurosci 12: 627-636. doi: 10.1038/nn.2297
    [139] Kameta N, Masuda M, Shimizu T (2012) Soft nanotube hydrogels functioning as artificial chaperones. ACS Nano 6: 5249-5258. doi: 10.1021/nn301041y
    [140] Song W, Soo Lee S, Savini M, et al. (2014) Ceria nanoparticles stabilized by organic surface coatings activate the lysosome-autophagy system and enhance autophagic clearance. ACS Nano 8: 10328-10342. doi: 10.1021/nn505073u
    [141] Wang W, Sreekumar PG, Valluripalli V, et al. (2014) Protein polymer nanoparticles engineered as chaperones protect against apoptosis in human retinal pigment epithelial cells. J Controlled release 191: 4-14. doi: 10.1016/j.jconrel.2014.04.028
    [142] Liao YH, Chang YJ, Yoshiike Y, et al. (2012) Negatively charged gold nanoparticles inhibit Alzheimer's amyloid-beta fibrillization, induce fibril dissociation, and mitigate neurotoxicity. Small 8: 3631-3639. doi: 10.1002/smll.201201068
    [143] Palmal S, Maity AR, Singh BK, et al. (2014) Inhibition of amyloid fibril growth and dissolution of amyloid fibrils by curcumin-gold nanoparticles. Chemistry 20: 6184-6191. doi: 10.1002/chem.201400079
  • This article has been cited by:

    1. Yekaterina Epshteyn, Chang Liu, Chun Liu, Masashi Mizuno, Nonlinear inhomogeneous Fokker–Planck models: Energetic-variational structures and long-time behavior, 2022, 20, 0219-5305, 1295, 10.1142/S0219530522400036
    2. Yekaterina Epshteyn, Chang Liu, Chun Liu, Masashi Mizuno, Local well-posedness of a nonlinear Fokker–Planck model, 2023, 36, 0951-7715, 1890, 10.1088/1361-6544/acb7c2
    3. Nicolas Boulanger, Fabien Buisseret, Victor Dehouck, Frédéric Dierick, Olivier White, Diffusion in Phase Space as a Tool to Assess Variability of Vertical Centre-of-Mass Motion during Long-Range Walking, 2023, 5, 2624-8174, 168, 10.3390/physics5010013
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(6642) PDF downloads(1095) Cited by(5)

Figures and Tables

Figures(3)  /  Tables(2)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog